Fundraising FoxADvantage Therapeutics
Miami, US · Founded 2021 · Delaware corporation · 1 known investors
Find your way into ADvantage Therapeutics
Sign up to see every warm intro you have to ADvantage Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the ADvantage Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Founders & leadership
AF
Agustin Fernandez Santana IIIExecutive
DB
David BuchsbaumExecutive
FM
Frank MattnerNamed on SEC filing
Board
WS
Walter SchmidtBoard director
Investors · 1
Reported raises · per SEC filings
Form D private placements$19M disclosed across 3 rounds · 2021–2023
▶$13.7MraisedJul 2025 · 24 investors · Other Health CareRule 506(b)
▶$13.7MraisedJul 2025 · 24 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Walter SchmidtDirector
- Agustin Fernandez Santana IIIExecutive Officer, Director
- Jeffrey B. MaddenExecutive Officer, Director
- David BuchsbaumExecutive Officer
- Frank MattnerDirector
- Offering amount
- $25.4M
- Amount sold
- $13.7M
- Finders' fees
- $5K
- Placement agents
- Corporate Partners & Co. LLC
- First sale
- Jun 2023
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
▶$275KraisedJun 2022 · 3 investors · Other Health CareRule 506(b)
▶$275KraisedJun 2022 · 3 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Walter SchmidtDirector
- Agustin Fernandez Santana IIIExecutive Officer, Director
- Frank MattnerDirector
- David BuchsbaumExecutive Officer
- Jeffrey B. MaddenExecutive Officer, Director
- Offering amount
- $7.5M
- Amount sold
- $275K
- First sale
- May 2022
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
▶$5MraisedJun 2021 · 1 investors · Other Health CareRule 506(b)
▶$5MraisedJun 2021 · 1 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Walter SchmidtDirector
- Jeffrey B. MaddenDirector
- Frank MattnerDirector
- Agustin Fernandez Santana IIIExecutive Officer, Director
- Offering amount
- $10M
- Amount sold
- $5M
- First sale
- Jun 2021
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 2
BioworldBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Applied TherapeuticsApplied Therapeutics is a biopharmaceutical company developing novel drugs for rare diseases with high unmet medical need. Its Aldose Reductase Inhibitor franchise is in development across disease areas including Galactosemia and SORD Deficiency.
Companies working in the same space as ADvantage Therapeutics.
Frequently asked questions
- Who are ADvantage Therapeutics's investors?
- ADvantage Therapeutics's investors include quadraScope Venture Fund.
- How much funding has ADvantage Therapeutics raised?
- ADvantage Therapeutics has disclosed $19M raised across 3 rounds.
- Where is ADvantage Therapeutics headquartered?
- ADvantage Therapeutics is headquartered in Miami, US.